| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $8.62B | +5.8% |
| Gross profit | $5.87B | — |
| Operating income | $2.67B | — |
| Net income | $1.82B | +5.1% |
| Gross margin | 68.2% | Net margin 21.1% |
| Segment | Revenue | Share |
|---|---|---|
| Product | $8.22B | 95.4% |
| Repathaevolocumab | $0.88B | 10.2% |
| Prolia | $0.73B | 8.4% |
| EVENITY | $0.56B | 6.5% |
| TEPEZZA | $0.49B | 5.7% |
| Otezla | $0.43B | 5.0% |
| BLINCYTO | $0.41B | 4.8% |
| Nplate | $0.41B | 4.8% |
| Xgeva | $0.41B | 4.8% |
| Product And Service Other | $0.40B | 4.6% |
| TEZSPIRE | $0.34B | 4.0% |
| Kyprolis | $0.33B | 3.8% |
| Enbrel | $0.32B | 3.7% |
| Aranesp | $0.31B | 3.6% |
| Vectibix | $0.29B | 3.3% |
| UPLIZNA | $0.26B | 3.0% |
| IMDELLTRAIMDYLLTRA | $0.26B | 3.0% |
| KRYSTEXXA | $0.26B | 3.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $2.74B | 31.8% |
| SG&A | $1.60B | 18.6% |
| Tax & other | $0.85B | 9.8% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
APH ・ ADI ・ AON ・ APA ・ APO ・ AAPL ・ AMAT ・ APP ・ APTV ・ ACGL ・ ADM ・ ARES
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies